Premium
Inhibition of the mitogenic, angiogenic and tumorigenic activities of pleiotrophin by a synthetic peptide corresponding to its C‐thrombospondin repeat‐I domain
Author(s) -
HammaKourbali Yamina,
BernardPierrot Isabelle,
Heroult Mélanie,
Dalle Sophie,
Caruelle Danièle,
Milhiet Pierre Emmanuel,
Fernig David G.,
Delbé Jean,
Courty José
Publication year - 2008
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.21191
Subject(s) - pleiotrophin , thrombospondin , angiogenesis , thrombospondin 1 , fibroblast growth factor , chemistry , heparin , growth factor , neurite , epidermal growth factor , peptide , biochemistry , microbiology and biotechnology , receptor , biology , in vitro , cancer research , metalloproteinase , matrix metalloproteinase
Pleiotrophin (PTN), is a heparin‐dependent growth factor involved in angiogenesis and tumor growth. PTN contains a thrombospondin repeat‐I (TSR‐I) motif in its two β‐sheet domains that are involved in its binding to heparin and its neurite outgrowth activity. Based on the importance of the binding of PTN to heparin in its dimerization and biological activities, we have designed two synthetic peptides, P(13–39) and P(65–97) corresponding to a part of the N‐terminal and C‐terminal TSR‐I motif of PTN, respectively. P(65–97) inhibited the mitogenic, tumorigenic and angiogenic activities of PTN, as well as the mitogenic and an angiogenic activity of fibroblast growth factor‐2 (FGF‐2). However, P(65–97) had no effect on the mitogenic activity of epidermal growth factor, which does not bind heparin. P(65–97) but not P(13–39) inhibited the binding of PTN and to a lesser extent of FGF‐2 to heparin using an immunoassay and an optical biosensor assay and bound directly to heparin with a K d of 120 nM. These findings suggest that P(65–97), containing amino acids 65–97 of the TSR‐I motif of the C‐terminal domain of PTN, inhibits the activities of PTN and FGF‐2 by virtue of its ability to bind heparin very effectively and so compete with the growth factors for their polysaccharide co‐receptor. J. Cell. Physiol. 214:250–259, 2008. © 2007 Wiley‐Liss, Inc.